Invokana
indicated to manage type 2 diabetes mellitus to support improved glycaemic control.
Strengths: 100mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
SGLT2 Inhibitor
- Pharmacological class
SGLT2 Inhibitor
- Minor side effects
urinary tract infection; vulvovaginal candidiasis; increased urination; thirst
- Moderate side effects
hypoglycaemia; postural hypotension
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Janssen
- Onset Time
1–2 hours
- Duration
24 hours
- Storage instructions
Store below 30°C.
- Drug interactions
Diuretics; Insulin
- Age restrictions
Not indicated for use in children.
Contraindications
hypersensitivity to canagliflozin; severe renal impairment; diabetic ketoacidosis
Precautions and warnings
maintain adequate hydration; monitor for genital mycotic infections; regular foot examination recommended
Serious side effects
diabetic ketoacidosis — requires immediate medical attention; necrotising fasciitis of the perineum — requires immediate medical attention
Patient summary
indicated to manage type 2 diabetes mellitus to support improved glycaemic control.
Mechanism of action
This medication functions by inhibiting the sodium-glucose cotransporter 2 in the kidney, which reduces the reabsorption of glucose into the bloodstream, increasing its elimination through urine.
Pregnancy and breastfeeding
Pregnancy: not recommended during second and third trimesters. Breastfeeding: not recommended.
Invokana
indicated to manage type 2 diabetes mellitus to support improved glycaemic control.
Editorial Notes
- Active ingredient(s): Canagliflozin
- Listed indication(s): Type 2 Diabetes Mellitus
Available option
- 30 tablets - 100 mg1482-100-mg-17722